Viking Therapeutics Inc (VKTX NASDAQ) stock market data APIs
$38.9327
-0.65(-1.7%)
as of December 5, 2025
Try our APIs with
free plan!
Viking Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Prev. Close
38.9327
Open
38.2842
High
39.6066
Low
37.9964
52 wk Range
18.92-51.6799
Market Cap
4 358 M
Shares Outstanding
113 M
EPS
-0.81
Beta
0.642
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Viking Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Viking Therapeutics Inc data using free add-ons & libraries
Get Viking Therapeutics Inc Fundamental Data
Viking Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-22
- EPS/Forecast: -0.67
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Viking Therapeutics Inc News
New
Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics
Biotech stocks and research shares diverged Thursday after reports suggested the FDA will soon require just one pivotal study. Continue Reading
LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock
Eli Lilly and Company’s LLY stock has been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early October. The 50-day moving average is a short-term indicator, ...
Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?
Eli Lilly LLY and Novo Nordisk NVO, long-standing rivals and the two dominant forces in the GLP-1 obesity market, are now locked in an intensified battle as both companies slash prices to defend and e...
LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website
Eli Lilly LLY announced that it has lowered the price of single-dose vials of its blockbuster obesity drug, Zepbound (tirzepatide), purchased through the direct-to-consumer (DTC) platform LillyDirect....
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
